Table 2.
Baseline patient characteristics of patients with lung adenocarcinoma at the start of pemetrexed treatment.
| MTAPlo/CDKN2Alo | Others | ||||
|---|---|---|---|---|---|
| Patient Characteristics | Na | (%) | Na | (%) | |
| All | 26 | (100%) | 46 | (100%) | |
| Age – median (min, max) | 60.5 | (34.0, 82.0) | 59.0 | (26.0, 76.0) | |
| Gender | Female | 16 | (67%) | 23 | (51%) |
| Male | 8 | (33%) | 22 | (49%) | |
| Race | Asian | 1 | (4%) | 1 | (2%) |
| Black | 1 | (4%) | 2 | (4%) | |
| White | 22 | (92%) | 42 | (93%) | |
| ECOG PS | 0 | 1 | (4%) | 2 | (4%) |
| 1 | 18 | (75%) | 40 | (89%) | |
| 2 | 5 | (21%) | 3 | (7%) | |
| Kras Mutation | No | 17 | (71%) | 31 | (69%) |
| Yes | 7 | (29%) | 14 | (31%) | |
| EGFR mutation | No | 14 | (58%) | 37 | (84%) |
| Yes | 10 | (42%) | 7 | (16%) | |
| Smoking Status | Current | 2 | (8%) | 6 | (13%) |
| Former | 10 | (42%) | 20 | (44%) | |
| Never | 12 | (50%) | 19 | (42%) | |
| Line of Therapy | 1 | 16 | (62%) | 32 | (70%) |
| 2 | 8 | (31%) | 8 | (17%) | |
| 3 | 1 | (4%) | 5 | (11%) | |
| 4 | 1 | (4%) | 0 | (0%) | |
| 6 | 0 | (0%) | 1 | (2%) | |
MTAPlo MTAP below-median expression, CDKN2Alo CDKN2A below-median expression, ECOG PS Eastern Cooperative Oncology Group performance status.
aPatients with unavailable information for a specific feature were not included, so counts may not always sum to 26 and 46.